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Chapter 1

Curcumin: A Folklore Remedy
from Kitchen on the Way
to Clinic As Cancer Drug
Debasish Bandyopadhyay
Department of Chemistry, The University of Texas-Pan American,
Edinburg, Texas, US

Dedicated to Professor (Dr.) John Miller Trant

Abstract
Numerous compounds are widely distributed in nature and many of these possess
medicinal/biological/pharmacological activity. Curcumin, a polyphenol derived from the
rhizomes (underground stems) of Curcuma longa Linn (a member of the ginger family,
commonly known as turmeric) is a culinary spice and therapeutic used in India for
thousands of years to induce color and flavor in food as well as to treat a wide array of
diseases. The origin of turmeric as spice and folklore medicine is so old that it is lost in
legend. Curcumin has many beneficial pharmacological effects which includes, but are
not limited with, antimicrobial, anti-inflammatory, antioxidant, antiviral, antiangiogenic,
and antidiabetic activities. Most importantly curcumin possesses immense
antitumorigenic effect. It prevents tumor formation in a number of animal models,
including models of lung, liver, stomach, colon, breast, esophageal cancer etc. A concise
discussion regarding the effects of curcumin on five leading cancers with respect to
cancer mortality (lung, liver, stomach, colorectal and breast) and associated molecular
mechanisms is included. The potential applications of curcumin as chemopreventive
agent, chemosensitizer, and radiosensitizer in both in vitro and in vivo studies have
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discussed in this chapter. In addition to natural drugs, a large number of synthetic drugs
(mainly organic and organometallic) are being used as medicines against cancer.
Synergistic role of two or more drugs against any particular disease plays an important
role in modern drug discovery research. Subsequently, preclinical and clinical studies of
drug synergy have become an intriguing part of translational research.
This chapter describes the pertinent recent examples of synergistic role of curcumin
with various other molecules with special emphasis to commercial drugs and natural
products. Curcumin has also demonstrated the ability to improve patient outcomes in
clinical trials.

Keywords: Cancer, Carcinoma, Adenocarcinoma, Sarcoma, Neoplasm, Apoptosis,
Angiogenesis, Cell death, Tumor, Toxicity, Carcinogenesis, Drug synergy, Synergistic
effect, Natural products, Heterocycles, Medicinal chemistry, Pharmacophore,
Pharmacology, Bioactive, Organometallics, Pharmaceutical

Abbreviations
3'-UTR
8-OHdG
ACEI
AFM
AIN
ALDH
AMP
AMPK
Apaf-1
ARNT
ATG5
Bak
Bax
Bcl- XL
Bcl-2
Bcl-Xs
BRCA1
CAF
CDK
Chk1
CHOP
COX-2
CTNND1
CTTN
CXCL1
DCLK1
DEN

Three prime untranslated region
8-Hydroxy-2′-deoxyguanosine
Angiotensin converting enzyme inhibitor
Atomic force microscopy
American Institute of Nutrition
Aldehyde dehydrogenase
Adenosine 5ꞌ-monophosphate
Adenosine 5ꞌ-monophosphate (AMP)-activated
protein kinase
Apoptosis protease-activating factor-1
Aryl hydrocarbon receptor nuclear translocator
Autophagy protein 5
Bcl-2-antagonist/killer
B-cell lymphoma-2-associated X protein
B-cell lymphoma-extra large
B-cell lymphoma-2
B-cell lymphoma-extra small
Breast cancer 1, early onset
Cancer-associated fibroblasts
Cyclin-dependent kinase
Checkpoint kinase 1
CCAAT/enhancer binding protein homologous protein
Cyclooxygenase-2
Catenin delta-1
Cortactin
Chemokine (C-X-C motif) ligand 1
Doublecortin-like kinase 1
Diethylnitrosamine
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DIABLO
EGCG
EGFR
Egr-1
ER
ErbB-2
Erk1/2
EZH2
FACS
FAS
FDA
FOXO1
GGTP
GSK3β
HER2
HIF-1
IGF-1R
IL-8
IκBα
JMJD2A
JNK
KDM4C
MAPK
Maspin
MDR
MEF
MMP
MMR
mRNA
MRP-1
MTT
NAFLD
NAT
NF-κB
NSCLC
NTR
PAK1
PARP
p-EGFR
p-Erk1/2
P-gp
PKB
PP2A
PP5

3

Direct inhibitor of apoptosis protein-binding protein with low
isoelectric point
(-)-Epigallocatechin-3-gallate
Epidermal growth factor receptor
Early growth response-1
Endoplasmic reticulum
Erythroblastic leukemia viral oncogene homolog 2
Extracellular signal-regulated kinase ½
Enhancer of zeste homolog 2
Fluorescent activated cell sorter
Fatty acid synthase
Food and Drug administration (United States)
Forkhead box protein O1
γ-Glutamyltranspeptidase
Glycogen synthase kinase 3β
Human epidermal growth factor receptor 2
Hypoxia-inducible factor-1
Insulin-like growth factor 1 receptor
Interleukin-8
Inhibitor of nuclear factor of kappa light polypeptide gene enhancer
in B-cells-α
Jumoji domain containing 2A
c-Jun N-terminal kinase
Lysine (K)-specific demethylase 4C
Mitogen-activated protein kinase
Mammary serine protease inhibitor
Multidrug resistance
Mouse embryonic fibroblast
Matrix metalloproteinase
Mismatch repair
Messenger RNA
Multidrug resistance-associated protein-1
3-[4,5-Dimethyl-2-thiazolyl]-2,5 diphenyltetrazolium bromide
Non-alcoholic fatty liver disease
N-acetyltransferase
Nuclear factor-κB
Non-small cell lung cancer
Neurotensin receptor
Serine/threonine p21-activated kinase 1
Poly ADP ribose polymerase
Phosphorylated epidermal growth factor receptor
phosphorylated Extracellular signal related kinase ½
P-glycoprotein
Protein kinase B (also known as Akt)
Phosphatases 2A
Phosphatases 5
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PPARα
PRP4B
PTPN1
Rac1
RNAi
ROS
RT-PCR
SCLC
siRNA
Smac
SREBP-1c
STAT3
T790M
TGF β1
TLR-4
TNBC
TNF-α
TOP2A
TPA
VEGF
VM
WHO
α-SMA

Peroxisome proliferator-activated receptor-α
Pre-mRNA processing factor 4B
Protein tyrosine phosphatase, non-receptor type 1
Ras-related C3 botulinum toxin substrate 1
RNA interference
Reactive oxygen species
Reverse transcription polymerase chain reaction
Small cell lung cancer
small interfering RNA
Second mitochondria-derived activator of caspase
Sterol regulatory element binding proteins-1c
Signal transducer and activator of transcription 3
T790M mutation results in an amino acid substitution at position
790 in EGFR, from a threonine (T) to a methionine (M)
Transforming growth factor β1
Toll-like receptor-4
Triple-negative breast cancer
Tumor necrosis factor-α
DNAtopoisomerase II alpha
12-O-tetradecanoylphorbol-13-acetate
Vascular endothelial growth factor
Vasculogenic mimicry
World Health Organization
α-Smooth muscle actin

1. Introduction
Natural products are intimate part of human civilization. It is impossible to say exactly
when menfolk started to take plant portions to cure various diseases. Medicinal plants have
been employed for thousands of years as remedies for human ailments because of the
presence of particular phytochemicals. Phytochemicals are the broad spectrum of compounds
derived from plants (―phyto‖ means plant in Greek). In practice, the term ―phytochemicals‖
refers to a wide variety of compounds found in plants, but is mainly used to describe those
plant natural products that may affect human/animal health, either in positive (as medicine) or
negative (as narcotic/poison) manner. One of the important classes of phytochemicals consists
of nutraceuticals. The term ―nutraceutical‖ was formed by the portmanteau of two different
words: nutrition and pharmaceutical. DeFelice (1989) defined [1] nutraceutical as ―any
substance that is a food or a parts of food, that provides medical or health benefits, including
the prevention and treatment of disease‖. Later, the definition was modified by Health Canada
and accordingly [2] nutraceutical is ―a product isolated or purified from foods that is
generally sold in medicinal forms not usually associated with food. A nutraceutical is
demonstrated to have a physiological benefit or provide protection against chronic disease‖.
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Polyphenols are a fundamental class of nutraceuticals which are widely used as
chemotherapeutic, chemoprotective as well as chemopreventive agents. Polyphenols are
important constituents of many fruits, vegetables and cooking spices.
Beverages like coffee, green and black tea, red wine, chocolate, nuts etcetera are good
source of polyphenols. It has been found that many polyphenols are strong antioxidant, antiinflammatory, cardioprotective, hepatoprotective and neuroprotective agents as well as
immune regulators, either by itself on in combination with others [3]. Curcuminoids are a key
category of polyphenols.

2. Origin and Historical Background
Curcumin (diferuloylmethane), the major constituent of curcuminoids, is present in
turmeric which is the dried powered rhizomes (underground stems) of Curcuma longa Linn
of the Zingiberaceae family. The medicinal use of turmeric (haridra) was indicated in
Sushruta Samhita, one of the three fundamental texts of Ayurveda (Indian traditional
medicine) in the 6th century BCE. Its medicinal uses were also found in Charaka Samhita
(300-500 BCE). As Indian traditional medicine (Ayurveda) turmeric has been using to treat a
broad range of common disorders for over 6000 years [4].
In India, turmeric is used as a cooking spice to induce nice yellow-orange color and
flavor in curries, pickles and chutneys. It is used worldwide as a color inducing agent as well
as preservative in American mustard, mayonnaise, butter and margarine and has been
designated as international food additive E100 [5]. Turmeric is in the GRAS (Generally
Recognized As Safe) list of the US Food and Drug Administration having GRN number 460
[6]. This royal spice was introduced to the western world in the 13th century by Marco Polo,
one of the early European explorers to the Indian subcontinent [7, 10]. Since then India is the
highest turmeric producing country in the world [8-10]. Turmeric has at least 76 synonyms
listed in the 1999 World Health Organization (WHO) monograph [11]. A few popular names
are Haridra (Sanskrit), Halood (Bengali), Haldi (Hindi), Kurkum uqdah safra (Arabic), Ukon
(Japanese), Chiang Huang (Chinese), Ulgeum (Korean), Kurkuma (German), Safran des
Indes (French), kurkumy (Russian), Indian saffron etc.
Besides its culinary appeal turmeric has a glorious history of uses as a therapeutic and
preventive agent against a wide array of disorders and diseases, either by itself or in
combination with other agents. As an ancient household remedy a hot poultice of turmeric
powder and slaked lime (chun-halood in Bengali) is applied locally to relieve muscular pain
and inflammation caused by sprain and injury.
In some parts of India, a drink made from fresh turmeric, ginger roots and honey in a
glass of hot milk are given to women twice daily after childbirth.
A poultice of fresh turmeric paste is also applied to the perineum as wound healing for
lacerations in the birth canal [12]. Its traditional uses as strong therapeutic or preventive agent
against several human diseases include, but are not limited to, diabetes, fibrosis, asthma,
rheumatism, allergies, inflammation, intestinal worms, atherosclerosis, diarrhea, dyspepsia,
intermittent fevers, biliousness, cough, sinusitis, constipation, jaundice, urinary discharges,
flatulence, leukoderma, amenorrhoea, acne, colic inflammation, respiratory ailments, lupus
nephritis, irritable bowel syndrome, menstrual difficulties, anorexia, coryza, hematuria,
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hemorrhage, neurodegenerative, Alzheimer‘s disease, and cancer [9, 12-16]. The presence of
turmeric is essential in most of the religious ceremonies in Hinduism.
The sequence of curcumin in natural product chemistry can be accessed as:
Natural products → Plant natural products → Phytochemicals → Nutraceuticals →
Polyphenols → Curcuminoids → Curcumin
In the same way the categorization of Curcuma longa Linn is shown in Table 1.
Depending upon the soil composition and geographical diversity, the chemical
composition of turmeric varies to some extent.
Table 1. Classification of Curcuma longa
Kingdom:
Division:
Class:
Subclass:
Order:
Family:
Genus:
Species:
Scientific Name:

Plantae
Magnoliophyta
Liliopsida
Zingiberidae
Zingiberales
Zingiberaceae
Curcuma
C. longa
Curcuma longa

The presence of about 235 compounds of which 109 sesquiterpenes, 68 monoterpenes, 22
diarylheptanoids and diarylpentanoids, 8 phenylpropene and other phenolic compounds, 5
diterpenes, 4 sterols, 3 triterpenoids, 2 alkaloids and 14 other compounds have been identified
in turmeric. Among the diarylheptanoids three compounds are curcuminoids, the major
pharmacologically active ingredients of turmeric. Curcumin, the major curcuminoid which
constitutes 3-5% of turmeric has been consumed for medicinal purposes for thousands of
years [14, 17]. Two other curcuminoids are demethoxycurcumin and bis-demethoxycurcumin
(Figure 1). Commercial curcumin is a mixture of three curcuminoids: curcumin (71.5%),
demethoxycurcumin (19.4%) and bis-demethoxycurcumin (9.1%) [14].
The isolation of curcumin, the principal constituent of turmeric responsible for its vibrant
yellow-orange color, first reported by Vogel and Pelletier [18] in 1815 from the plant
Curcuma longa as ―yellow coloring-matter‖ and named as ―curcumin‖. Later, it was found to
be a mixture of resin and turmeric oil [19]. Curcumin was isolated in 1842 but the chemical
formula was not reported [19, 20]. The chemical structure of curcumin as diferuloylmethane
was identified by Milobedzka et al. in 1910 and the first synthesis of curcumin was reported
from the same laboratory in 1913 [19, 21, 22]. The chemical structure of curcumin was
confirmed in 1973 [23] and a few years ago in 2007, its solution structure was reported [24].
There are at least 125 plants under the genus Curcuma but curcuminoids have been
identified only from 7 Curcuma plants [3, 10, 25, 26] till date.
As mentioned earlier, Curcuma longa Linn is the major source (3-5% curcuminoids) of
curcuminoids and curcumin. Curcuminoids are also reported from C. phaeocaulis (1-3%
curcuminoids), C. xanthorrhiza (1-2% curcuminoids), C. zedoaria (~ 0.1% curcuminoids), C.
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aromatic (< 0.1% curcuminoids), C. comosa (< 0.1% curcuminoids), and C. mangga (< 0.1%
curcuminoids). Curcuminoids have also been identified in other genera like Costus speciosus,
Etlingera elatior, Zingiber cassumunar etc.
Besides the ancient literature, the first scientific report related to the medicinal uses of
Curcuma was published in 1748 [27, 28]. After 67 years a review detailing the biological and
medicinal properties of turmeric (curcumin) was published [18]. In 1937, Oppenheimer
reported the medicinal activity of turmeric against biliary diseases [29].
In 1949, Schraufstatter and Bernt reported [30] the antibacterial activity of curcumin and
its pharmacological activity to cure eye disease was reported [31] by Chaudhri in the
following year. Jiang and co-workers evaluated the anticancer activity of four natural
products viz. camptothecin, harringtonin, cantharidin and curcumin on human tumor biopsies
in an in vitro soft agar clonogenic assay system and reported their findings in 1983 [32].

Figure 1. Structure of Curcuminoids.

Table 2. Comparative statistics of Curcumin research (1801-2013)
Year(s)
1801-1900
1901-1950
1951-1980
1981-1990
1991-2000
2001-2010
2011
2012
2013
[keyword: curcumin].

SciFinder
Scholar
17
92
373
264
1101
7073
1576
1948
1797

PubMed
Central
0
1
6
5
75
2505
1282
1637
1233
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They reported curcumin as ―relatively ineffective‖ antitumor agent than camptothecin,
and harringtonin. Probably this was the first evaluation of curcumin against cancer. Kuttan
and colleagues published the anticancer activity of curcumin in 1985 [33].
The acceptance of traditional medicine is considered as an alternative form of modern
health care system. Over the past quarter century there has been growing interest in a possible
role of curcumin on various diseases. The research topic ―curcumin‖ in any chemistry/health
related search engine hits a huge number of results, including research articles, reviews,
communications, patents, books, editorials etc. Comparative results obtained up to December
31, 2013 from the two major chemistry and health related databases viz. SciFinder Scholar
and PubMed Central are presented in Table 2 and Figure 2. After publication of the initial
studies on curcumin as a promising anticancer agent in the mid-eighties [32, 33], scientists
from all over the world paid their attention to this novel nutraceutical. It is now established
that cancer is neither a single disease nor a comparatively new disease.

Figure 2. Growing interest (comparative statistics) on Curcumin research.

3. Curcumin and Cancer
It is well-known that cancer is a leading cause of death worldwide and accounted for 8.2
million deaths in 2012 among which 70% occur in low and middle income countries.
According to the World Health Organization the annual cancer cases will rise from 14 million
in 2012 to 22 within the next two decades [34, 35].
On the other hand, cancer is a group of more than 200 neoplastic diseases caused by the
dysregulation of multiple factors [36]. Therefore, there is a continuous need to introduce new
anticancer agents to reduce both cancer incidence and cancer-related mortalities.
Moreover, cancer cells often adapt to develop resistance to chemotherapeutic agents,
consequently a better understanding of anticancer agents induce or inhibit carcinogenesis
could lower tumor incidence or provide help to manage this disease effectively. Current
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research in this field directs to develop novel chemotherapeutic agents, which are more potent
tumor-selective cytotoxic agents and can circumvent drug resistant cancer cells. A tentative
estimation states that about 25% drugs are still derived from the Mother Nature and 74-80%
of all cancer drugs have their origins in natural products i.e. these drugs are modified natural
products [37, 38].
Several scientists around the world are actively engaged to investigate the anticancer
activity of the ancient natural product curcumin. Consequently a huge number of publications
detailing its anticancer activity have been published. A concise discussion regarding the
effects of curcumin on five leading cancers with respect to cancer mortality viz. lung, liver,
stomach, colorectal and breast (Figure 3) can be found in the sequel. The outcome of some
important and comparatively recent studies have been summarized in this chapter.

3.1. Lung Cancer
The overall percentages of occupancy (13.0) and mortality (19.4) of lung cancer were
highest worldwide among all cancers in 2012 [34, 35, 39]. About 85-90% lung cancers are
non-small cell lung carcinoma (NSCLC) and 5-year prevalence is only 5.8%. The
chemotherapeutic and chemopreventive activities of curcumin against lung cancer have been
reported. Singh and co-workers reported [40] that Curcumin can behave as a potential
adjuvant chemotherapeutic agent against NSCLC by enhancing chemotherapeutic effect of
the drug Vinorelbine (trade name Navelbine) in H520 cells in vitro. Independent treatment of
Cucumin and Vinorelbine induced 23.7% and 38% apoptosis respectively whereas
pretreatment with Curcumin amplified Vinorelbine induced apoptosis to 61.3%.
The mechanism of action suggested that Curcumin triggered apoptosis by enhancing the
protein expression of Bax and Bcl-Xs while the protein expression of Bcl-2 and Bcl-XL was
reduced. Consequently, release of apoptogenic Cytochrome c took place, and the activity of
Caspase-9 and Caspase-3 boosted. Here it is important to mention that Bcl-XL is a protein
consisted by 233-amino acids associated with antiapoptotic properties.
On the other hand, one of the alternatively spliced transcripts of the Bcl-x gene codes for
the protein Bcl-xS, which lacks 63 amino acids present in Bcl-xL and associated with
proapoptotic activity. Lev-Ari et al. exposed the non-small cell lung cancer PC-14 cells for
72h to curcumin (0-50 μM) and apoptosis was determined by FACS analysis. Finally, the
COX-2, EGFR, ErbB-2 and p-Erk1/2 expressions were measured by Western blot analysis.
The results showed that inhibitory effect of Curcumin on survival and apoptosis of lung
cancer cell lines was significantly higher in the COX-2-expressing cells than in the COX-2deficient cells. Curcumin decreased COX-2, EGFR and p-Erk1/2 expressions in a dosedependent manner [41]. Radhakrishna-Pillai et al. demonstrated Curcumin-induced apoptosis
in two human lung cancer cell lines A549 (adenocarcinomic human alveolar basal epithelial
cells) and H-1299 (also known as NCI-H1299 or CRL-5803).
Upon Curcumin treatment the growth of both the cell lines was inhibited in time and
concentration dependent manner [42]. In the presence of 40 mM curcumin a decrease in
expression of p53, bcl-2, and bcl-XL was observed after 12 h exposure while Bak and Caspase
genes remained unchanged up to 60 mM curcumin but showed decrease in expression levels
at 80 – 160 mM. It was suggested that the apoptotic cell death by curcumin involves multiple
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pathways. Curcumin up-regulates various pro-apoptotic genes and simultaneously downregulate some of the anti-apoptotic genes. Homo-dimerization or hetero-dimerization of these
pro- and anti-apoptotic genes in favor of apoptosis was one of the suggested mechanisms of
Curcumin-induced apoptosis. The mechanistic pathway by which Bax and Bak, two
multidomain pro-apoptotic Bcl-2 family members, regulate curcumin-induced apoptosis was
revealed by Shankar et al. [43]. The study involved the use of mouse embryonic fibroblasts
(MEFs) deficient in Bax, Bak or both genes. The treatment with Curcumin caused an
escalation in the protein levels of both Bax and Bak, and mitochondrial translocation.

*

All cancers excluding non-melanoma skin cancer. Specific type of cancer and its percentage of
contribution toward cancer related mortality in 2012 can be shortened [39] as: Lip, oral cavity
(1.8), Nasopharynx (0.6), Other pharynx (1.2), Gallbladder (1.7), Pancreas (4.1), Larynx (1.1),
Melanoma of skin (0.7), Kaposi sarcoma (0.3), Corpus uteri (0.9), Ovary (1.9), Testis (0.1),
Kidney (1.7), Brain, nervous system (2.3), Thyroid (0.5), Hodgkin lymphoma (0.3), Non-Hodgkin
lymphoma (2.4), Multiple myeloma (1.0), Leukaemia (3.2).

Figure 3. Mortality due to Cancer in 2012 (worldwide).

Consequently mitochondrial membrane potential dropped which favored the cytosolic
release of apoptogenic molecules such as Cytochrome c and Smac/DIABLO from
mitochondria to cytosol to activate caspase-9 and caspase-3 and eventually apoptosis. The
authors also suggested that Curcumin-induced caspase activation might be amplified due to
induction of Apaf-1 because it also caused an increase in the protein level of Apaf-1 in wildtype MEFs. Taken together, both Bax and Bak are essential for curcumin-induced apoptosis,
and over-expression of Smac/DIABLO as interventional approach to combat with Baxand/or Bak-deficient chemoresistant cancers for curcumin-based therapy.
Cisplatin (or cisplatinum, or cis-diamminedichloroplatinum[II]) has been using as a novel
anticancer drug against several types of cancer for the past more than three decades
(Figure 4, Synthesis: 1970; FDA approval: 1978).
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However, the efficiency of Cisplatin-based chemotherapy can‘t reach to its expected
level; because of de novo drug resistance in the advanced stage of cancer or in cancer cells
acquiring cisplatin resistance during therapy. It has been found that the late detection and
growing drug resistance are the two main causes of high mortality due to lung cancer [39].
Under this circumstances, the chemosensitization strategy might be beneficial to fight
against lung cancer. As an excellent chemosensitizer, Curcumin can sensitize Cisplatinmediated apoptosis in human non-small cell lung cancer H460 cells.
The mechanism involves the generation of superoxide anion and down-regulation of the
anti-apoptotic Bcl-2 protein through proteasomal degradation and subsequent sensitization of
the cancer cells to Cisplatin-assisted apoptosis.

Figure 4. Example of drugs demonstrated synergistic effect with Curcumin.

In a nutshell, treatment of the non-small cell lung cancer H460 cells with Cisplatin using
Curcumin as chemosensitizer resulted in reversal of Bcl-2-facilitated cisplatin resistance and
consequently increased apoptosis [44].
Not only as chemotherapeutic and/or chemosensitizing agent, Curcumin also
demonstrated its chemopreventive activity immensely against lung cancer. It is known that
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TNF-α and oxidants activate transcription factors such as NF-κB, which is involved in the
transcription of proinflammatory mediators, including Interleukin 8 (IL-8).
It was found [45] that the treatment of cultured alveolar epithelial cells (A549) with
hydrogen peroxide (100 µM) and TNF-α (10 ng/ml) the NF-κB and activator protein-1
(AP-1) activation were increased significantly and IL-8 was released. The treatment with
Curcumin inhibited both hydrogen peroxide and TNF-α-mediated activation of NF-κB and
AP-1; the release of IL-8 was inhibited also.
Moreover, an increased level of glutathione and glutamylcysteine ligase catalytic subunit
mRNA expression were observed in curcumin-treated A549 cells in comparison to untreated
cells.
The study suggested that curcumin contains multiple properties like (i) it can act as an
oxygen radical scavenger, (ii) antioxidant through modulation of glutathione levels, and (iii)
anti-inflammatory agent through inhibition of IL-8 release in lung cells. It is known that the
drug Erlotinib (an EGFR-tyrosine kinase inhibitor, Figure 4) can produce satisfactory result in
human lung adenocarcinoma PC-9 cells by inducing apoptosis. However Erlotinib exhibited
weaker effect on Erlotinib-resistant H1975 (or NCI-H1975) and H1650 (NCI-H1650) human
lung cancer cells than Curcumin pretreated Cisplatin. The combination of Curcumin and
Erlotinib showed similar effects on apoptosis as the combination of Curcumin and Cisplatin
in Erlotinib-resistant non-small cell lung cancer cell lines. In addition, this combination
(Curcumin and Erlotinib) significantly increased the cytotoxicity of Erlotinib to Erlotinibresistant NSCLC cells and reduced the tumor growth in xenograft mouse model.
The mechanism of action involves the down-regulation of the expressions of EGFR, p-EGFR,
and survivin, and inhibition of the NF-κB activation by sustaining IκB expression level in
Erlotinib-resistant NCI-H1650 and NCI-H1975 cells [46]. The primary reason of Erlotinibresistance in lung cancer includes T790M mutant EGFR receptor and c-Met gene
amplification. It has been found [47] that coadministration of Curcumin and Erlotinib in PC-9
lung cancer cells accelerated apoptosis by elevation of IκB expression. Also the
coadministration of Curcumin and Erlotinib to siRNA-pretreated PC-9 lung cancer cells
significantly increased the cytotoxicity by reducing the cell viability because of synergistic
effect. This combination remarkably reduced the tumor growth in mice. The efficacy of
Curcumin on the growth and metastasis of H1975 (NSCLC) in an intralung tumor mouse
model has been reported [48] using ectopic and orthotopic lung tumor mouse models.
The control group was given AIN-076 control diet whereas the investigating group received
same food in addition to 0.6% curcumin 14 days prior to cell implantation and until the end of
the experiment. The orthotopic tumor was generated by percutaneous injection of the lung
cancer cells in Matrigel into the left lung of CD-1 nude mice. The successive Western blot
analysis exhibited that the expressions of IkB, nuclear p65, COX-2 and p-ERK1/2 were
down-regulated by curcumin in vitro. A 36% decrease in weight of intralung tumors of
orthotopic human NSCLC xenografts with sufficient increase in survival rate of the
investigating group was observed. Cigarette smoke is considered as one of the main reasons
of lung carcinogenesis. The presence of carcinogens such as Benzo[a]pyrene, the free radicals
like hydroxyl radicals, superoxide radicals have the required potential to activate NF-κB
which can inhibit apoptosis, stimulate proliferation and mediate tumorigenesis. Accordingly
NF-κB is an ideal target for preventing cigarette smoke-mediated lung carcinogenesis.
The effect of Curcumin on cigarette smoke-induced NF-κB activation and NF-κB-regulated
gene expression was studied in H1299 (human non-small cell lung carcinoma), A549 (human
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lung epithelial cell carcinoma), and BEAS-2B (immortalized human bronchial epithelial)
cells [49]. The results showed that pre-treatment with curcumin stopped the cigarette smokeprompted DNA-binding of NF-κB and NF-κB-dependent reporter gene expression.
Tissue invasion and metastasis are considered as one of the hallmarks in cancer. It has
been found that relapse and/or metastasis are very common for lung cancer patients after
complete excision of the cancer, even if they were at stage IA [50]. The protein Rac1 is
widely related in cytoskeleton rearrangements (occur in physiological events such as cell
movement. Cytoskeletal defects are frequently associated with cancer metastasis.) and
migration, invasion as well as metastasis of cancer cells. Curcumin inhibits EGF or TGF β1induced 801D lung cancer cell migration and invasion [51].
The decrease in the metastasis in curcumin-treated cells was anticipated due to the
inhibition of Rac1/PAK1 pathway signaling and the decreased MMP-2 and MMP-9
expression. The anti-invasion activity of curcumin was confirmed by the relation between
Rac1 and the growth and metastasis inhibitory effect of curcumin in vivo by the xenograft
model. In another investigation [52] the growth inhibitory effect of Curcumin in both the nonsmall cell lung cancer (A549) and small cell lung cancer (SCLC) H460 (human) cell lines
have been reported. The study suggested that Curcumin can prevent cell proliferation by the
upregulation of CDK inhibitors, p27 and p21, and downregulation of Cyclin D1 although the
compound precludes progression and metastasis through induction of FOXO1.
An interesting synergism of Curcumin with another important phytochemical Resveratrol
(trans-3,5,4'-Trihydroxystilbene, Figure 4) against lung carcinogenesis has also been reported
[53]. The Benzo[a]pyrene treatment in mice resulted in a substantial increase in the protein
expression of phosphorylated p53 [specifically at ser15] which confirmed p53 hyperphosphorylation while enzyme activities of caspase 3 and caspase 9 were observed to be
potentially reduced. The combined treatment of Curcumin and Resveratrol to benzo[a]pyrene
treated mice resulted in a significant decrease in p53 hyper-phosphorylation as well as
regulation of cellular metabolism enzymes and caspases.

3.2. Liver Cancer
Liver cancer was the second leading cause of cancer related deaths (9.1%) worldwide in
2012 which accounted only 1.9% five-year prevalence [39]. In general, hepatocellular
carcinoma is resistant to standard chemotherapy. Surgery or liver transplantation at the early
stage may provide longer survival to the patients. However, about 80% of liver cancer
patients with advanced stage are not amenable to liver transplantation or surgery and this is
the main reason of poor prognosis in liver cancer [54]. Hence it is highly challenging to
identify/develop effective drug to combat liver cancer. Curcumin demonstrated its
antiproliferative activity against human HCC (hepatocellular carcinoma) cells by arresting the
cell cycle in G2 and regulating Wnt signaling pathway [55]. The proliferation is inhibited by
apoptosis in a dose-dependent manner. The interruption of Wnt signaling takes place by
reduction of β-catenin activity, which in other word suppresses the expression of β-catenin
target genes (VEGF, Cyclin D1 and c-myc). The Wnt signaling pathway is considered as an
important factor for the development, growth, survival, proliferation and metastasis of the
cancer cells. The GSK3β and β-catenin play the major role in this pathway and therefore, a
few factors associated with this pathway are considered as potential targets for anticancer
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therapy. Curcumin demonstrated the anti-migratory activity by suppressing the TPA-induced
activation of the Wnt signaling and the related cell migration in Hep3B liver cancer cells [56]
in vitro and tumor growth in vivo.
The molecular mechanism of Curcumin-induced apoptosis in human liver cancer (Huh7)
cells was studied [57]. It is known that Fas ligand (FasL or CD95L) is a type-II
transmembrane protein that belongs to TNF (tumor necrosis factor) family. Upon Curcumin
treatment of Huh7 cells significant increase in Fas and FasL, caspase-3 activation as well as
PARP cleavage have been observed. Rapid activation of p-38 under the influence of
Curcumin triggers apoptosis via p-38-dependent up-regulation of FasL. High expression of
FAS is associated with many types of cancer including liver cancer.
It has been found that Curcumin can down-regulate FAS expression to inhibit its
intracellular activity and mRNA level in a concentration-dependent manner in HepG2 liver
cancer cells in vitro. Curcumin induced apoptosis in HepG2 liver cancer cells with the IC50
value of 8.84 μg/mL determined by MTT assay. Not only FAS, the siRNA also showed similar
result with Curcumin [58]. From flowcytometric analysis it was concluded that up-regulation of
the expression of tubulin occurred by the treatment with Curcumin in HepG2 liver cancer
cells. Treatment with Curcumin caused cell-cycle arrest at G2/M phase with concomitant
losses from G0/G1 phase in a concentration-dependent manner.
The AFM imaging demonstrated that the membrane toxicity and cytoskeleton destruction
may be the therapeutic targets of Curcumin [59].
It has been cited in many literatures that during oxidative stress the expression of TLR-4
is regulated. Excessive intracellular ROS production up-regulates TLR-4/2 expression
whereas elimination of ROS by specific scavengers inhibits the up-regulation of TLR-4
expression and suppresses transcription of TLR-4 mediated genes. Therefore it is considered
that ROS triggers the TLR-4 signaling pathway [60]. On the other hand, Myd-88 is a downstream adaptor molecule of TLR-4 to conduct signals to begin translocation of NF-κB and
activation of MAPKs which ultimately leads to cell death via apoptosis. The initiator of the
caspase cascade, caspase-8, is activated by cleavage through the interaction with Fas-linked
death domain via Myd-88. The executor of apoptosis in caspase cascade, caspase-3, can also
be activated by cleavage after the activation of caspase-8 [61]. Curcumin-induced inhibition
of cell proliferation as well as cell death through apoptosis in MHCC97H human liver cancer
cell lines followed the sequence: activation of ROS → TLR4/Myd-88 → activation of
Caspase-3/Caspase-8 [62]. The apoptosis occurred in a dose-dependent manner through
activating intracellular ROS generation. The augmented intracellular ROS formation
stimulated the TLR-4/MyD-88 signaling pathway.
Consequently the activation of caspase-8 and caspase-3 surfaced, which ultimately led to
apoptosis in MHCC97H human liver cancer cells.
Vasculogenic mimicry (VM) is considered as one of the major factors in cancer invasion
and it denotes the process in which the cancer cells mimic endothelial cells by forming blood
channels. The potential of Curcumin on vasculogenic mimicry of human liver
adenocarcinoma cells (SK-Hep-1) has been studied in vitro. Curcumin inhibited vasculogenic
mimicry, decreased cell migration and MMP9 (matrix metalloproteinase-9) production of the
cancer cells. Curcumin exhibited the anti-VM efficacy by down-regulating the Akt (or PKB)
and STAT3 signaling pathways [63].
Two-dimensional electrophoresis and mass spectral investigations were carried out to
reveal the effect of Curcumin on the proteome of human liver cancer HepG2 cell lines [64].
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The HepG2 cells were treated with Curcumin (30 μmol/L) and the proteins were separated.
An up-regulation of cyclin-dependent kinase inhibitor 2A, carnitine deficiency-associated
gene, replication protein A2 and protein disulfide isomerase was noted whereas downregulation of Nm23 protein, Stathmin 1/oncoprotein 18, Ran binding protein 1, endoplasmic
reticulum-60 protease and proliferating cell nuclear antigen were noted. The data indicated
that Curcumin treatment might led to inhibit tumor growth, promote apoptosis by arresting
cell cycle, and prevent tumor invasion as well as metastasis.
The anti-atherosclerosis and hypolipidemic efficiencies of Curcumin might correlate with
promotion of the transmembrane transport of fatty acids and maintain the stability of the cell
membrane.
Hypoxia of solid tumor is one of the major problems to treat cancer. This situation arises
when the cells are deprived of required oxygen. As a tumor develops, it promptly outgrows its
blood supply, leaving portions of the tumor with areas where the oxygen concentration is
significantly lower than in healthy tissues. Hypoxic microenvironements in solid tumors are
in result of available oxygen being consumed within 70 to 150 μm of tumor vasculature by
fast growing tumor cells thus limiting the amount of oxygen available to diffuse further into
the tumor tissue. To support continuous growth and cell proliferation in hypoxic
environments, cancer cells are found to alter their metabolism. Hypoxia-inducible factor-1
(HIF-1) plays a key role in cellular responses to hypoxia counting the transcriptional
activation of a number of genes those are involved in tumor angiogenesis [65]. HIF-1 is
composed of HIF-1a and aryl hydrocarbon receptor nuclear trans-locator (ARNT). It was
reported that between these two subunits of HIF-1; ARNT was found to be attacked by
curcumin in several cancer cell types, including mice bearing Hep3B liver cancer cell lines
and in xenografted tumors. Curcumin activated the proteasomal degradation of ARNT
through oxidation and ubiquitination processes to suppress ARNT, erythropoietin, and VEGF
(a major HIF-1 target angiogenic factor) leading to overall down-regulation of HIF-1 in
tumors [66]. In brief, the study showed that the anticancer effect of Curcumin in tumor
hypoxia was because of ARNT degradation which caused HIF-1 inactivation. In the case of
human liver cancer (HepG2) cells in vitro Curcumin treatment significantly reduced the
hypoxia-mediated HIF-1 protein level by repressing the expression of VEGF in vascular
endothelial cells which eventually inactivated the transcriptional activity of HIF-1 under
hypoxia. Consequently, curcumin efficiently blocked the hypoxia-stimulated angiogenesis of
vascular endothelial cells. These findings supported that Curcumin might play major roles in
tumor suppression through the inhibition of HIF-1-mediated angiogenesis [66].
It has been stated earlier that the invasion of cancer cells is considered as an important
and distinctive step toward metastasis. The blockage of this physiological incident by
medicines or supplements/nutraceuticals prolongs the life span of an affected host. Kozuki et
al. suggested [67] that antioxidative property of Curcumin might be involved in its antiinvasive effect. The authors evaluated the efficacy of Curcumin on the proliferation and
invasion of the rat ascites hepatoma AH109A cells in vitro and ex vivo. To satisfy this goal, a
co-culture system of the hepatoma cells with mesothelial cells derived from rat mesentery
was subjected for invasion study. Curcumin reduced the hepatoma slipping motility in a
concentration-dependent manner up to 5 µM and afterward maintained the effect up to 20 µM
with a minimum impact on cell proliferation.
Interestingly, the sera isolated from rats, those consumed Curcumin orally, also inhibited
the AH109A cellular invasion when added to the culture medium. Curcumin and curcumin-
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containing rat sera inhibited the ROS-potentiated invasive capacity by concurrently treating
AH109A cells with hypoxanthine, xanthine oxidase and either of Curcumin samples.
Curcumin demonstrated synergism with other anticancer agents against a number of
cancers including liver cancer. Curcumin along with EGCG (a natural polyphenol, mainly
present in green tea, white tea and in black tea with low abundance, Figure 3) exhibited
inhibition against acrylamide (a proven rodent carcinogen)-induced human liver cancer
HepG2 cell proliferation. Acrylamide (≤100 μM) induced CYP2E1 expression potentially and
knockdown of CYP2E1 restrained acrylamide to increase viability of HepG2 cells [68].
Moreover, acrylamide up-regulated EGFR, Cyclin D1 and NF-κB, which contributed to cell
proliferation.
Curcumin and EGCG successfully down-regulated the protein expression of CYP2E1,
EGFR, Cyclin D1 and NF-κB signaling pathway. Accordingly subsequent inhibition of
acrylamide-induced HepG2 cell proliferation was observed. Prevention of angiogenesis
signifies a fascinating approach to hepatocellular carcinoma as it is one of the hypervascular
solid tumors. Curcumin demonstrated synergistic effect in combination with two other drugs
namely: leﬂunomide (an antirheumatic drug) and perindopril, an angiotensin converting
enzyme inhibitor (ACEI), against DEN-induced hepatocellular carcinoma in mice [69]. DEN
was administered to the mice for a period of eight weeks and a notable increase in
immunohistochemical staining of CD31-positive endothelial cells and consequently hepatic
microvessel density (MVD) was observed as compared to normal liver. Following the trend,
up-regulation of HIF-1α and VEGF was noticed in the DEN-treated mice in comparison to
their normal counterpart. Monotherapy with leﬂunomide and perindopril showed week
inhibition whereas Curcumin demonstrated down-regulation of HIF-1α.
The combined therapy of these three agents (Curcumin, leﬂunomide and perindopril)
resulted synergism through suppression of VEGF expression and exhibiting inhibitory action
on neovascularization and subsequent inhibition of angiogenesis. Nowadays it is well-known
that metastasis of liver is a major cause of mortality in colorectal cancer (CRC). Curcumin in
combination with ulinastatin (a glycoprotein which acts as urinary trypsin inhibitor) inhibited
CRC liver metastases in human colorectal cancer cell lines HCT-116 in vitro through
modulation of MMP-9 and expression of E-cadherin. Because of the synergistic role of
Curcumin along with ulinastatin (Figure 3) the inhibition of HCT-116 cell migration and
invasion occurred [70]. The synergism of Curcumin and ulinastatin was also evaluated in
mouse model through dynamically tracking the development of tumor and its therapeutic
responses by bioluminescence imaging. A prolonged survival of tumor-bearing mice those
treated with the combined agents (Curcumin and ulinastatin) was noticed.
Besides the above, Curcumin confirmed its activity to prevent the undesirable fat
accumulation in human hepatocarcinoma cells [71]. It is known that NAFLD (Non-alcoholic
fatty liver disease) is one of the major metabolic syndromes globally, caused by the
accumulation of liver triglycerides (TG). The underlying reason of NAFLD is an imbalance
between uptake, synthesis, export, and oxidation of fatty acids. Curcumin demonstrated
hypolipidemic effect by suppressing lipid accumulation and TG as well as total cholesterol
(TC) levels in oleic acid-induced human HepG2 liver cancer cells. In the first stage,
Curcumin enhanced AMPK phosphorylation to stop the anabolism and promote catabolic
pathway by up-regulating PPARα and down-regulating the activity SREBP-1c and FAS to
reduce hepatic lipogenesis.
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Because of low bioavailability and half-life, a small portion of the orally administered
Curcumin can reach at the site of action. Therefore, Curcumin metabolites have been assumed
to be responsible for its bioactivity. Curcumin glucuronide (Figure 5) was reported as the
major metabolite present in the plasma after oral administration of Curcumin in rats [72].
An interesting study was carried out by Nakagawa and co-workers to compare the
activity of Curcumin and its major metabolite Curcumin glucuronide (synthetic) on gene
expression in HepG2 human liver cancer cell lines in vitro. The RT-PCR (Reverse
transcription polymerase chain reaction) was used to detect the RNA expression levels. The
effect of Curcumin and Curcumin glucuronide on mRNA expression of ACOX1, GSTT1,
CAT, and AREG genes was studied. IL-8 expression was also evaluated by real time RT-PCR,
because Curcumin inhibits IL-8 production.

Figure 5. Curcumin glucuronide: the major metabolite of Curcumin.

The results showed that the expression of all the tested genes (ACOX1, GSTT1, CAT,
AREG, and IL-8) was significantly decreased by Curcumin treatment, whereas the effect of
Curcumin glucuronide was found to be very low.
Curcumin glucuronide down-regulated the expression of GSTT1 to some extent only. In
brief, the in vitro cell culture study suggested that Curcumin per se was highly active, rather
than its major metabolite Curcumin glucuronide.

3.3. Stomach Cancer
Stomach cancer remains one of the major health issues globally. It is the third leading
cause of cancer death worldwide with a five-years prevalent of 4.7% in 2012. Anticancer
activity of Curcumin on various stomach cancer cells was investigated. It successfully
inhibited the cell proliferation of BGC-823 (human stomach adenocarcinoma), MKN-45
(human gastric adenocarcinoma) and SCG-7901 (human gastric cancer) cell lines in a
concentration- (1, 5, 10 and 30 μM) and time- (24, 48, 72 and 96 h) dependent manner by
inducing apoptosis [73]. Annexin A5 affinity assay (a test to quantify the number of cells
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undergo apoptosis; the assay uses the protein annexin A5 to tag apoptotic and dead cells, and
the numbers are then counted using either flow cytometry or by a fluorescense microscope)
confirmed that apoptosis occurred at the dose of 10 and 30 μM when the cells were treated for
24 and 48 h. Total protein analysis revealed that Curcumin up-regulated 33 proteins and
down-regulated 42 proteins as determined by spot densitometry. A total of 52 proteins with
substantial Mascot scores (Mascot is a software search engine that uses mass spectrometry
data to identify proteins from peptide sequence databases) were identified, those were
associated with cancer development and progression. The siRNA targeting Chk1 (Checkpoint
kinase 1) sensitized the SCG-7901 cells to undergo Curcumin-mediated apoptosis. In another
study Curcumin inhibited the fore stomach carcinogenesis induced by benzo[a]pyrene [B(a)P]
and micronuclei formation induced by cyclophosphamide in mice [74].
The therapeutic potential of chemotherapy to combat stomach cancer is limited because
of chemoresistance which is associated with the expression of NF-κB. Etoposide and
doxorubicin are two well-studied anticancer agents with ability to suppress the growth of
human gastric cancer SGC-7901 cells in a time- and concentration-dependent manner. The
drug synergy of Curcumin in combination with etoposide (Figure 4) or doxorubicin (Figure 4)
was studied [75]. Application of Curcumin in addition to etoposide or doxorubicin suppressed
the proliferation of SGC-7901 human gastric cancer cell lines. Inhibitory rate was found to
be: etoposide vs. (etoposide + curcumin), 35% vs. 48%, p<0.05 and doxorubicin vs.
(doxorubicin + curcumin) 33% vs. 45%, p<0.05. The results showed that Curcumin
intensified the antitumor effects of etoposide and doxorubicin by inhibiting the up-regulation
of NF-κB and NF-κB-regulated anti-apoptotic downstream targets Bcl-2 and Bcl- XL. The
combination of Curcumin and the anticancer agents (etoposide or doxorubicin) showed
substantial possibility to become an effective therapy for gastric cancer that could synergize
the effect of chemotherapeutics and overcome chemoresistance.
The anticancer effect of Curcumin on human gastric carcinoma (AGS), normal gastric
epithelial cell line (GES-1) and human gastric cancer cell (MGC-803) was studied. It was
found that Curcumin induced apoptosis in the cancer cells and the cytotoxicity was selective
toward cancer cells in comparison to normal cells. The molecular mechanism was
investigated in human gastric carcinoma (AGS) cell lines. An increased externalization of
phosphatidylserine residue was observed by Annexin 5/PI staining along with amended
cleavage of procaspase-3, -7, -8 and -9. The study revealed [76] that apoptosis was led by
curcumin mediated ER stress and mitochondrial dysfunction as evidenced by expression of
CHOP protein, phosphorylation of JNK and repression of SERCA2ATPase, discharge of
Cytochrome c, reduction of Bcl-2 and fall of mitochondrial membrane potential. Notably,
curcumin reduced cytosolic and ER Ca2+, but augmented mitochondrial Ca2+ in the two cell
lines which played key role to induce apoptosis leading to cell death. Curcumin inhibited the
AGS cell proliferation in a time- and concentration-dependent manner (p<0.05) causing 34%
decrease at 5 μmol/L, 51% at 10 μmol/L, and 92% at 25 μmol/L after 96 hours of treatment. It
was interesting to note that when curcumin (10 μmol/L) was removed after a 24 hours
exposure, the growth pattern of curcumin-treated AGS cells was similar to that of control
cells, suggesting reversibility of curcumin on the progression of AGS cells [77].
The combined therapy of Curcumin and 5-fluorouracil (5FU, a pyrimidine analog; it is a
suicide inhibitor and works through irreversible inhibition of thymidylate synthase, Figure 4)
inhibited the AGS cell proliferation considerably in comparison to either Curcumin or 5-FU
monotherapy suggesting the synergistic effect of Curcumin with 5-FU against AGS human
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gastric cancer cells. It was also found that 96 hours administration of Curcumin (10 μmol/L)
in AGS gastric cancer cells, the G2/M phase fraction of the Curcumin treated cells was 60.5%
in comparison to 22.0% of the control group, suggesting a G2/M block by Curcumin.
Multidrug resistance (MDR) is a severe problem in cancer chemotherapy. It is often
related with the overexpression of ATP-dependent drug efflux proteins belonging to the
superfamily of ATP-binding cassette (ABC) transporters namely (i) P-glycoprotein (P-gp,
170 kDa) encoded by the MDR1 gene and (ii) multidrug resistance-associated protein-1
(MRP-1, 190 kDa) encoded by the MRP-1 gene. These proteins bind to and transport various
structurally unrelated compounds to maintain their intracellular concentrations below
cytotoxic levels [78, 79].
Vincristine (brand name, Oncovin, abbreviation: VCR, Figure 4) is a vinca alkaloid
isolated from the plant Cantharanthus roseus. It is a coupled alkaloid of vindoline and
cantharanthine, biosynthesized in the plant. Being a potent mitotic inhibitor it is one of the
frontline cancer drugs and belongs to WHO‘s list of essential medicines [80]. The ability of
Curcumin to act as a chemosensitizer to sensitize the vincristine (drug) resistant human
gastric cancer cells SGC7901/VCR to undergo apoptosis was studied [81]. It increased the
sensitivity of SGC7901/VCR cells to vincristine consistently with an increase in intracellular
drug concentration by decreasing P-gp function and expression. It is known that Pglycoprotein (P-gp) plays an important role to prevent cell death not only by removing
(efflxing) drugs from the cell, but also by inhibiting the activation of proteases associated to
initiate (caspase-8) [82] and to execute (caspase-3) apoptotic signaling [82, 83]. Treatment by
Curcumin on drug-resistant SGC7901/VCR cells stimulated vincristine-induced caspase-3
activation. P-gp was up-regulated in SGC7901/VCR cells, whereas it was suppressed, at least
to some extent, after a 24 hours treatment with Curcumin (10 μmol/L). Resistant cells treated
with 1 μmol/L vincristine itself showed 77% lower levels of caspase-3 activation relative to
SGC7901 cells, but the activation of caspase-3 in the resistant cell line increased by 44%
when cells were treated with vincristine accompanied by Curcumin. Taken together,
Curcumin reversed the MDR of the human gastric carcinoma SGC7901/VCR cell line and it
could be considered as a promising chemosensitizer of MDR in gastric cancer.
N-nitroso-N-methylurea (NMU) is a strong carcinogen, mutagen, and teratogen. It holds
the potential to alkylate the nucleobases in nucleic acids by transferring its methyl group,
which eventually leads to AT:GC transition mutations. Curcumin treatment on NMU and
saturated sodium chloride-induced gastric cancer in male Wistar rats was investigated [84].
At the initiation period Curcumin successfully reduced the gastric cancer through downregulation of phosphorylated IκBα and 8-OHdG expressions. Besides the above, Curcumin
successfully demonstrated its potential as a chemopreventive agent in Phase I clinical trial in
patients with high-risk or pre-malignant lesions of gastric cancer [85].

3.4. Colorectal Cancer (Colon Cancer)
Colorectal cancer is the fourth leading cause of cancer-related mortality worldwide in
2012 with a five-years prevalent of 10.9%. The molecular intricacies of colon tumors are not
fully understood. In vitro studies in human colorectal carcinoma HCT-116 cell line [86]
showed the overexpression of a few histone demethylases such as JMJD2A, JMJD2B and
JMJD2C but not JMJD2D. Moreover, despite of close homology of JMJD2A-C, their
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intracellular localizations were different. JMJD2A was mainly localized in cytoplasm and
nucleus, JMJD2B preferred to be localized in nucleus only whereas JMJD2C was strongly
attached with chromatin. The protein JMJD2C (also known as KDM4C) played crucial roles
to develop tumor (HCT-116 cells) by complex formation with β-catenin (an oncoprotein) and
promoting its up-regulation. JMJD2C also helped to up-regulate the growth stimulatory
proteins FRA1, Cyclin D1 and survival factor Bcl-2. Curcumin exhibited its potential to
reduce the activity of JMJD2 enzymes through down-regulation. It was proposed that
Curcumin induced sustained activation of JNK, which in turn stimulated apoptosis as a result
of inhibition of NFkB transcriptional activity in human colorectal carcinoma (HCT-116) cell
line [87].
Later, the same authors reported that it was not essential for Curcumin to inhibit NF-κB
for its anti-apoptotic effects rather other unidentified regulators [88] might be involved in cell
death process. A study carried out by Wang et al. [89] revealed that neurotensin (an intestinal
hormone that was potently released by fat ingestion) acted via the native high-affinity
neurotensin receptor (NTR) increased the secretion and up-regulation of IL-8 in a
concentration- and time-dependent manner. This activation implicated Ca2+-dependent
protein kinase C, extracellular signal-regulated kinase-dependent activator protein-1, and
extracellular signal-regulated kinase-independent nuclear factor-κB (Ca2+/PKC, ERK/ AP-1,
and NF-κB) pathways. These effects eventually enhanced the HCT-116 cell proliferation and
migration. Curcumin successfully inhibited gastrointestinal hormone (e.g., neurotensin)induced chemokine up-regulation and subsequent cell migration. It is known that the enzyme
DNAtopoisomerase II alpha (TOP2A) is upregulated in several cancers and acts on
RNApolymerase II transcription on chromatin templates. On the other hand, CTCF (also
known as 11-zinc finger protein or CCCTC-binding factor, a multifunctional transcription
factor) recruits the largest subunit of RNA polymerase II (LS Pol II) and this recruitment of
LS Pol II is more pronounced in proliferating cells than in fully differentiated cells.
As expression of imprinted genes is often altered in tumors, the therapeutic effect of
Curcumin on transcription of the imprinted H19 gene was investigated [90] in HCT 116 and
another human colon adenocarcinoma (SW 620) cell lines. It was concluded that Curcumin
down-regulated the TOP2A and subsequently inhibited RNA polymerase II-dependent
transcription and eventually - gene transcription was inhibited.
Curcumin inhibited the proteasome and induced apoptosis in both HCT-116 and
metastatic SW480 human colon adenocarcinoma cell lines [91]. This study confirmed
proteasome as an important cellular target of Curcumin. In silico docking studies between
proteasome and Curcumin showed that two carbonyl carbons of the Curcumin (Figure 1)
were highly susceptible to a nucleophilic attack by the hydroxyl group of the N-terminal
threonine of the proteasomal chymotrypsin-like (CT-like) subunit. As a result, Curcumin
inhibited the proteasome activity in human colon cancer HCT-116 and SW480 cell lines
which directed to accumulation of ubiquitinated proteins, several proteasome target proteins,
and subsequent induction of apoptosis in vitro. The effect was confirmed in animal model
through intragastric administration of Curcumin to ICR SCID mice bearing xenografts of
colon cancer HCT-116 cells. The experiment resulted in significant inhibition of tumor
growth because of proteasomal inhibition which repressed cell proliferation and stimulated
cell death via apoptosis. It was reported that only 3–5% of all colorectal cancers are due to
hereditary genetic defects and up to 25% of patients might have some degree of familiarity
for this disease whereas majority of colorectal cancers take place in an erratic fashion without
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any documented family history. In addition to genetic instability phenotypes such as
chromosomal and microsatellite instability, epigenetic alterations that include DNA
methylation modifications, histone alterations and variations in miRNA expression might be
responsible for the initiation and progression of increasing incidences of colorectal cancers
[92, 93]. The effect of Curcumin on DNA methylation of three colorectal cancer cell lines
such as HCT116, HT29 (human colorectal adenocarcinoma) and RKO (human colon cancer)
was studied [94]. It was found that Curcumin might exhibit its anti-cancer activity, at least in
part, via epigenetic modulation of DNA methylation changed only in a subset of genes those
were distinct from the generalized genomic hypomethylation related with amplified genomic
instability in colorectal cancer cells.
Autophagocytosis (or Autophagy, in Greek: auto means self and phagein means to eat) is
a basic catabolic mechanism which involves the degradation of unnecessary or dysfunctional
cellular components in cell via the actions of lysosomes. The breakdown of cellular
components promotes cellular survival during starvation by maintaining cellular energy
levels. Depending upon the state of the disease, autophagy may be a response to stress that
promote survival whereas in other cases it appears to promote morbidity or cell death [95,
96].
A study carried out by Mosieniak et al. with HCT-116 cell lines concluded that despite of
its low bioavailability, Curcumin could demonstrate good anticancer activity because of
cellular senescence of the cancer cells [97]. It was reported that the senescence of cancer and
normal cells contained many common features and the senescence of HCT116 cells was
correlated with the induction of autophagy. In the case of p53+/+ HCT116 cells,
overexpression of the p53 and p21 proteins was observed whereas p53-independent induction
of p21 was observed in p53-/- HCT116 cells. The correlation between autophagy and
senescence was established by electron microscopy observations of autophagosomes, LC3-II
up-regulation, punctue staining of LC3 and increased content of acidic vacuoles in the
curcumin-treated cells. However, inhibition of autophagy, due to the reduced expression of
Autophagy protein 5 (ATG5) by RNAi reduced the number of senescent cells promoted by
curcumin, but did not lead to increased cell death. Another study targeted doublecortin-like
kinase 1 (DCLK1), a cancer stem cell marker, to enhance anticancer activity of Curcumin.
At optimum concentrations, curcumin significantly decreased expression levels of stem cell
markers (DCLK1/CD44/ALDHA1/Lgr5/Nanog) in three-dimensional spheroid cultures and
tumor xenograft models derived from colon cancer cells. However, Curcumin surprisingly
induced proliferation and autophagic survival of a subset of DCLKl-positive cancer stem cells
[98].
Conversely, the combination of DCLK1-siRNA and Curcumin could intensely reverse
the phenotype of cancer stem cells. The RNAi-mediated silencing of DCLK1 activated
Curcumin-induced apoptotic cell death of colon cancer cells in vitro and in vivo.
Cortactin (cortical actin binding protein CTTN, a monomeric protein located in the
cytoplasm of cells), encoded by the CTTN/EMS1 gene, is a v-Src substrate localized with
cortical actin at the plasma membrane and is up-regulated in several types of cancer [99].
The phosphorylated form of cortactin (pTyr421) plays major role in cancer cell migration and
invasion. It was shown that pTyr421-cortactin was up-regulated in colon cancer.
Curcumin interacted with PTPN1 tyrosine phosphatases to rise its efficacy leading to
dephosphorylation of pTyr421-CTTN. Curcumin considerably reduced the pTyr421-CTTN in
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HCT116 cells and SW480 (adenocarcinoma of the colon) cells, but was ineffective in HT-29
(human colorectal adenocarcinoma) cells.
Altogether, Curcumin modulated the activity of PTPN1 phosphatase to reduce cortactin
phosphorylation and interaction with CTNND1, and finally to reduce colon cancer cell
migration [100]. Curcumin activated MAPKs including Erk1/2 and JNK and inhibited
phosphatases 2A (PP2A) and 5 (PP5). Up-regulation of MAPK cascade induce ROS which
ultimately led to p53-independent apoptosis in cancer cells [101].
Treatment with Curcumin destroyed wild-type p53 HCT-116 cells and mutant p53 HT-29
cells in a concentration- and time-dependent fashion. Curcumin treatment also exhibited
equivalent cytotoxic effect in p53+/+ and p53-/- HCT-116 cells, validating that curcumininduced cytotoxicity was independent of p53 status. Therefore, Curcumin holds the
therapeutic potential to combat with the colorectal tumors those are resistant to conventional
chemotherapy due to defects in p53 expression or function [102].
Curcumin treatment on other colorectal cancer cell lines was also investigated. Curcumin
repressed the proliferation of HCT-15 (human colorectal adenocarcinoma) cells by inducing
apoptosis in a time- and concentration-dependent manner [103]. The apoptotic pathway was
proposed by activation of caspase-3, down-regulation of pre-mRNA processing factor 4B
(PRP4B) and generation of ROS. Curcumin-induced inhibition of proliferation in HT-29
(human colon adenocarcinoma) and Caco-2 (heterogeneous human epithelial colorectal
adenocarcinoma) proceeded by repression of EGFR [104].
The process was initiated by the interruption of the ERK signal pathway by downregulating ERK and subsequently its activity was reduced. Accordingly the transcription
factor early growth response-1 (Egr-1) was suppressed and Egr trans-activity was reduced
which finally down-regulated the EGFR expression leading to inhibition of colon cancers
(HT-29 and Caco-2) cell proliferation.
Treatment with Curcumin could successfully inhibited the proliferation of human colon
cancer (COLO 205) cells through apoptosis, in concentration- and time-dependent manner, by
the generation of Ca2+ and ROS, followed by attenuation of the levels of mitochondria
membrane potential and finally the activation of caspase-3 [105].
The same research group also reported that Curcumin attenuated the N-acetyltransferase
(NAT) activity in a concentration-dependent manner in COLO 205 cells. Moreover Curcumin
treatment also reduced the DNA adduct formation and down-regulated gene (NAT1) mRNA
expression [106].
The treatment of colorectal cancer is challenging because of drug resistance. In particular,
more than 15% patients are found to be resistant to 5-Fluorouracil (5-FU, Figure 4) derived
chemotherapeutic agents. Accordingly, the colorectal tumor relapses in case of more than
50% patients. Curcumin demonstrated promising chemosensitizing activity to sensitize DNA
mismatch repair (MMR)-proficient 5-FU-resistant colon cancer cells HCT116R,
HCT116+ch3R (complemented with chromosome 3) in high density 3D culture which
resulted in improved fragmentation of colonospheres, increased apoptosis and related growth
inhibition [107]. Curcumin drawn considerable interest to serve as radiosensitizer in
colorectal cancer radiotherapy. Radio-resistance can be facilitated by constitutively active
pro-survival signaling pathways or by inducible/acquired mechanisms in response to radiation
therapy. The NF-κB activation was characterized as a mechanism of inducible radioresistance in colorectal cancer (HCT116, HT29, and SW620) cells.
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For the Curcumin-pretreated cells the resistance can be successfully overcome and better
radiotherapeutic effect can be achieved [108]. Curcumin inhibited the proliferation and the
post-irradiation clonogenic survival of colorectal cancer cells.
It also down-regulated the radiation-induced NF-κB activation through inhibition of
radiation-induced phosphorylation, repressing NF-κB-regulated gene products (Bcl-2, Bcl-xL,
inhibitor of apoptosis protein-2, cyclooxygenase-2, and cyclin D1) and inhibition of Akt
phosphorylation.
Curcumin showed synergistic activity with various drugs/compounds against colorectal
cancer cell lines. This activity can be summarized as shown in Table 3.
Apart from the above discussion, the Phase I trial of oral Curcumin was carried out which
advocated for its Phase II evaluation in the prevention or treatment of cancers outside the
gastrointestinal tract [116]. A recent clinical pilot study aimed to quantify levels of
curcuminoids in colorectal mucosa of patients after administration of oral curcumin [117]
yielded promising results and recommended the regimen as safe, and patients support its use
in long-term trials.
Table 3. Synergistic effect of Curcumin against colorectal cancer
Cell (s)

Drug/Compound*

HT-29

5-FU

HCT116 and HCT116+ch3
(complemented with
chromosome 3)

5-FU

HT-29

Ritanserin

Chemo-resistant HCT-116
and HT-29
HCT-116
HCT-116

Dasatinib
Dasatinib
Resveratrol

HT-29, IEC-18-K-ras, Caco2 and SW-480
*
See Figure 4.

Celecoxib

Mechanism of action
Inhibition of COX-2
expression.
Inhibition of NF-κB and Src
protein kinase signaling
pathways.
Suppression of the serotonin
5-HT2A receptor.
Down-regulation of CD133,
CD44, CD166 and ALDH.
Not known.
Inhibition of constitutive
activation of EGFR and its
family members and IGF1R.
Inhibition of COX-2 and
other non-COX-2 pathways.

Reference
[109]
[110]
[111]
[112]
[113]
[114]

[115]

3.5. Breast Cancer
The incidence of breast cancer (both sexes) was second highest among all cancers
(11.9%) and it was the leading cause of mortality due to cancer among women worldwide
(fifth for both genders) in 2012 [39]. Several research laboratories around the world have
been engaged to investigate the pharmacological potential of Curcumin against different types
of breast cancer. Curcumin could successfully inhibit the proliferation of human breast cancer
MDA-MB-435 cells in a concentration- and time-dependent manner by accumulating the
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cells in the G1 phase of the cell cycle. The overexpression of EZH2 in human breast cancer
MDA-MB-435 cells caused poor prognosis in this type of cancer. The underlying molecular
mechanism of Curcumin treatment was explained by the activation of the MAPK signaling
pathway. Three major members of the MAPK family, the p38 kinase, JNK and ERK were
stimulated to down-regulate the enhancer of zeste homolog 2 (EZH2) gene overexpression
leading to proliferation of the cancer cells [118]. Activated cancer-associated fibroblasts
(CAFs) or myofibroblasts facilitate the growth of tumor as well as develop drug-resistance in
human breast cancer. Hence effective therapeutic regimen should be able to inhibit the
paracrine effects of these supportive cells. Treatment with Curcumin on patient-derived
primary breast CAF cells overexpressed p16INK4A and other tumor suppressor proteins while
inactivated the JAK2/STAT3 pathway. This repressed the alpha-smooth muscle actin
(α-SMA) and consequently the cell migration/invasion was reduced [119]. Curcumin also
down-regulated Lamin B1 and initiated DNA damage-independent senescence in
proliferating but not inactive breast stromal fibroblasts. Curcumin-induced senescence was
p16INK4A-dependent and occurred with no associated inflammatory secretory phenotype.
Approximately 15% of all breast cancers are triple-negative breast cancer (TNBC).
In TNBC, the reoccurrence of tumor rate is high with poor prognosis and low survival rate.
TNBC is characterized by the lack expression of progesterone receptor (PR), estrogen
receptor (ER) and epidermal growth factor receptor 2 (HER2/cerbB2/EGFR2) expression
[120, 121]. Therefore, TNBC lacks effective targeted therapies. The only possible therapeutic
option in the adjuvant or metastatic situation is chemotherapy but most unfortunately TNBC
is often resistant to standard chemotherapeutic regimens. Consequently, TNBC has the worst
prognosis and survival rate of all breast cancer subtypes. Curcumin demonstrated its ability to
inhibit the proliferation of MDA-MB-231 TNBC cells inducing apoptosis in vitro by
inhibiting the EGFR signaling pathway [122]. The level of apoptosis of the curcumin-treated
(30 μmol/mL) group (26.34%) was significantly different from that of the control group
(2.76%). All these findings suggest that further studies with Curcumin are required,
particularly in this subset of breast cancer patients, for those proper treatment opportunities
are very limited. The anti-breast cancer effect of Curcumin was also evaluated with three
other TNBC cells such as MDA-MB-468 (MDA468), HCC1937, and HCC1806 by Nahta and
co-workers [123]. Besides these, HER2-overexpressing SKBR3 cells, ERα (+) MCF7 human
breast cancer cells, and non-transformed mammary epithelial MCF12A cell lines were also
evaluated with Curcumin. The molecular mechanism was described by the DNA damage in
TNBC cells along with phosphorylation, increased expression, and cytoplasmic retention of
the BRCA1 protein. Moreover, Curcumin induced apoptosis and anchorage-independent cell
growth (which is considered as a hall mark in cancer biology) and subsequent migration of
TNBC cells. In case of non-transformed mammary epithelial MCF12A cells apoptosis and
BRCA1 protein modulation were not observed which might be considered as target
specificity of curcumin toward TNBC cells.
To evaluate the anticancer effect of the dietary antioxidant Curcumin on mammary
cells which are resistant to oxidative damage, human breast cancer cells ZR-75-1 were treated
with Curcumin and CuSO4 in order to assess cell proliferation and GGTP
(γ-glutamyltranspeptidase) activity. Curcumin demonstrated cytotoxicity toward ZR-75-1
cells and down-regulated GGTP activity in a concentration-dependent manner. It induced
apoptosis and exhibited antioxidant effect only on the copper-oxidized cells. Taken together,
Curcumin inhibited the proliferation of human breast cancer ZR-75-1 cells under oxidative
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stress through apoptosis [124]. In another study it was revealed that Curcumin induced antiproliferative effect on two human breast cancer cell lines (MDA-MB-231 and BT-483) in a
concentration- and time-dependent manner via apoptosis [124]. The results showed that the
expression of Cyclin D1 was down-regulated in MDA-MB-231 cells whereas CDK4
expression was down-regulated in BT-483 breast cancer cells. On the other hand, MMP1
mRNA expression was significantly down-regulated in both the breast cancer cells.
Altogether it was concluded that Curcumin-induced anti-proliferative effect was due to
suppression of NFκB inducing genes [125]. To investigate whether Curcumin-induced cell
proliferation and apoptosis in human breast cancer MDA-MB-231 cell lines were associated
with down-regulation of Notch1 gene expression as well as NF-κB suppression, the mRNA
and protein expression of Notch1 and NF-κB were measured by RT-PCR and Western blot
[126]. The results showed that the mRNA and protein levels of Notch1 and NF-κB were
reduced considerably in concentration- and time-dependent manner (P < 0.05). From this
observation it was concluded that the Notch-1 signaling pathway was mechanistically linked
with NF-κB activity during curcumin-induced inhibition of cell growth and cell death through
apoptosis in human breast cancer MDA-MB-231 cell lines.
It was also supported that Curcumin-induced apoptosis in human breast cancer MCF-7
cells was accompanied by an increase in p53 level as well as its DNA-binding activity
followed by Bax expression at the protein level [127].
Human epidermal growth factor receptor 2 (HER2 or HER2/neu) is an oncogene and its
overexpression plays a key role in the growth and progression of certain aggressive type of
breast cancers with higher relapse rate, and increased mortality. It has become an important
biomarker and therapeutic target of about 20-30% of breast cancer patients [128]. HER-2 is
an important oncoprotein overexpressed in about 15-25% of breast cancers. It was
hypothesized that the ability of curcumin to down-regulate HER-2 oncoprotein and inhibit the
signal transduction pathway of PI3K/Akt, MAPK, and NF-κB activation may be important in
the treatment of HER-2-overexpressed breast cancer. The therapeutic potential of Curcumin
to down-regulate HER-2 oncoprotein was investigated in five human breast cancer cells:
MCF-7, MDA-MB-231, MCF-10A, BT-474, and SK-BR-3-hr (a herceptin resistant strain
from SK-BR-3) in vitro. The HER-2-overexpressed BT-474 xenograft model was used for in
vivo validation of Curcumin on HER-2-overexpressed breast cancer. Curcumin successfully
reduced the cell proliferation in all the five tested breast cancer cell lines. The Western blot
analysis showed that the phosphorylation of Akt, MAPK, and expression of NF-κB were
reduced in BT-474 cells, but not in SK-BR-3-hr cells, after treatment with herceptin. When
treated with curcumin, the HER-2 oncoprotein, phosphorylation of Akt, MAPK and
expression of NF-κB were decreased in both BT-474 and SK-BR-3-hr cells. In the BT-474
xenograft model, though not as much as herceptin, Curcumin effectually reduced the tumor
size [129].
Circulating tumor cells (CTC) are present into the vasculature from a primary tumor and
flow in the bloodstream. Therefore, CTCs can be considered as seeds for subsequent growth
of additional tumors (metastasis) in distant organs, initiating a mechanism that is responsible
for the vast majority of cancer-related deaths [130]. As stated earlier, invasion and metastasis
are two serious problems for the prevention/treatment of cancer. The properties of circulating
tumor cells (CTC) and cancer stem-like cells (CSC) are related with distant metastasis, but
the mechanisms through which CSCs promote metastasis are not clear. It was reported that
breast cancer cell lines with more stem-like properties display higher levels of microtentacles
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(McTN), a type of tubulin-based protrusion of the plasma cell membrane that forms on
detached or suspended cells and aid in cell reattachment. Curcumin promptly quenched
McTN in breast CSC, preventing reattachment from suspension.
Overall, a model in which breast CSCs with cytoskeletal alterations that promote McTNs
can mediate attachment and metastasis but might be targeted by Curcumin as an antimetastatic strategy [131]. Chronic inflammation is a key risk factor for the growth and
metastatic development of cancer. Curcumin inhibited the expression of the proinflammatory
cytokines CXCL1 and -2 to reduce breast and prostate cancer metastases. From the
microarray miRNA expression analysis it was found that Curcumin modulated the expression
of a series of miRNAs, including up-regulation of miR181b, in metastatic breast cancer
MDA-MB-231 cells where miR181b down-regulated the proinflammatory cytokines CXCL1
and -2 through a direct binding to their 3'-UTR. Curcumin-induced up-regulation of miR181b
in metastatic breast cancer cells inhibited metastasis formation in vivo in immune-deficient
mice [132]. Another study in this field suggested that metastatic development in human
mammary epithelial carcinoma MCF-7 cells was inhibited by Curcumin via the suppression
of urokinase-type plasminogen activator by NF-κB signaling pathways [133].
MMP-9 is a major factor in cancer cell invasion. An invasion-related study in MCF-7
human breast cancer cells [134] supported that Curcumin suppressed the TPA-induced MMP9 expression and subsequent cell invasion.
The molecular mechanism involved Curcumin-induced inhibition of PKCα-dependent
MMP-expression, down-regulation of NF-κB and reduction of AP-1 activation i.e. repression
of the PKCα, MAPK and NF-κB/AP-1 pathway in MCF-7 cells.
It has been found that breast cancer is often associated with obesity. Most probably the
relation between these two factors is mediated by adipokines. Visfatin [Nicotinamide
phosphoribosyltransferase (NAmPRTase or Nampt) also known as pre-B-cell colonyenhancing factor 1 (PBEF1)] is an adipokine, that is localized to the bloodstream and has
various functions. The protein visfatin has recently been shown to be related to the
development and progression of breast cancer.
Consequently, suppression of the gene visfatin might be a novel strategy to fight against
breast cancer. The influence of Curcumin on visfatin gene suppression was investigated [135].
It was found that the mRNA and protein levels of visfatin were down-regulated by Curcumin
in human breast cancer MDA-MB-231, MDA-MB-468, and MCF-7 cell lines. In addition, the
activity of constitutive nuclear factor (NF)-κB was reduced.
Taken together, visfatin could enhance the invasion of breast cancer cells which was
down-regulated by Curcumin. Furthermore, visfatin knockdown by siRNA led to the
reduction of cancer cell invasion. Curcumin treatment could impose anti-migratory activity in
human breast cancer MDA-MB-231 cells [136]. It inhibited proliferation and migration by
increasing the Bax to Bcl-2 ratio and decreasing NF-κBp65 expression. Integrin (α6β4) is a
laminin adhesion receptor with an established role in the invasion and migration of cancer
cells. Curcumin successfully decreased the integrin (α6β4)-dependent breast cancer cell
motility and invasion in a dose-dependent manner without affecting apoptosis in MDA-MB435/β4 (β4-integrin transfectants) and MDA-MB-231 breast cancer cell lines [137].
Maspin (mammary serine protease inhibitor) can suppress tumor growth and metastasis
in vivo and tumor cell motility and invasion in vitro in breast cancer. The maspin expression
in Curcumin-treated MCF-7 (wild type p53) at transcription and translation levels was
analyzed by RT-PCR, immunofluorescence, and Western blotting.
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The results showed a correlation of maspin expression with p53 and Bcl-2 levels.
Curcumin inhibited cell proliferation by inducing apoptosis and up-regulation of maspin gene
expression was observed in MCF-7 cells.
These findings were further correlated with the up-regulation of p53 protein and downregulation of Bcl-2, suggesting maspin mediated apoptosis in MCF-7 cancer cells [138]. The
chemopreventive activity of Curcumin in transformed breast cells was investigated [139].
Curcumin inhibited H-ras-induced invasive phenotype in MCF10A human breast epithelial
cells (H-ras MCF10A); repressed MMP-2 and exerted cytotoxic effect on H-ras MCF10A
cells in concentration-dependent manner. The apoptotic cell death involved significant downregulation of Bcl-2 and up-regulation of Bax.
Curcumin treatment resulted in the generation of ROS in H-ras MCF10A cells. In brief,
the results supported that curcumin inhibited invasion and induced apoptosis in the
transformed breast cancer H-ras MCF10A cells.
Drug-synergy has also been demonstrated by Curcumin with several other drugs against
breast cancer cell lines. A brief description is outlined below (Table 4):
Table 4. Synergistic effect of Curcumin against breast cancer
Drug/Compound*

Cell (s)

Mechanism of action
Reference
Apoptotic cell death via Akt
LY290042 (PI3K
phosphorylation and GSK3β [140]
inhibitor, Figure 4)
up-regulation

MCF-7

TNBC cells:
MDA-MB-468,
MDA-MB- 231, Doxorubicin
BT-549, and BT20
MCF-7

MDA-MB-231

MDA-MB-231

Inhibition of TGF-β and
PI3K/AKT signaling
pathways

[141]

Inhibition of GRP58mediated DNA cross-linking
Mitomycin C
[142]**
through the ERK/p38 MAPK
pathway
Inhibition of paclitaxelinduced activation of NF-κB
Taxol (Paclitaxel) and potentiation of the
[143]
growth inhibitory effect of
paclitaxel
Alteration of mitochondrial
Xanthorrhizol
transmembrane potential:
[144]
Apoptosis

*

See Figure 4.
Curcumin reduces the side effects of mitomycin C.

**

3.6. Miscellaneous
Aside from the previous discussion, anticancer effect of Curcumin was evaluated for
many other types of cancer. Some representative examples are summarized in Table 5.
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Conclusion and Future Aspects
Curcumin is a non-toxic, cheap and easily available natural polyphenol with high
medicinal and commercial demands. Many costly products can be derived from Curcumin.
For example, Curcumin can easily be converted to vanillin through a single-step conversion
[172].
However, a huge number of preclinical and early-phase clinical studies undoubtedly
confirmed that Curcumin, the golden spice [173] from India, is safe with vast potential of
becoming an effective drug for several human diseases including chronic inflammation and
cancer. Moreover, the results of clinical trials are under progress in different parts of the
world. A serious concern regarding pharmacological application of Curcumin is its poor
pharmacokinetics (PK) profile. The bioavailability of Curcumin is low because of poor
absorption, rapid elimination and/or low target organ concentration. This is due to the reason
that Curcumin is conjugated when it is absorbed through the intestine, consequently free
curcumin is present at extremely low level in the target organ.
Moreover, in biological system it is rapidly converted to its metabolites. Nevertheless,
Curcumin is non-toxic with a dose of 8g/day is well tolerable and 12g/day may cause minor
adverse effects like diarrhea, headache, yellowish stools and rashes etc.
Table 5. Anticancer activity of Curcumin on different types of cancer
Cancer type/Cell
Oral
SAS and SAS/luc
(transfected with luc gene)

Description/Mechanism of action

Reference

SAS cancer cell proliferation was greatly inhibited in vitro
and in vivo (xenograft model). Apoptosis: G2/M phase
arrest.

[145]

Nasopharyngeal
Detroit 562 and HONE-1
NPC/CNE2
CNE-2Z

Inhibition of cell proliferation inducing apoptosis via
caspase-3-dependent pathway.
Dark cytotoxicity and photocytotoxicity: Apoptosis
Inhibit cell proliferation by apoptosis. Alters expression of
proteins in the ERK-1/2 signaling pathway.

[146]
[147]
[148]

Oesophageal (Esophageal)
OE19, OE21, OE33 and
KYSE450
TE-7, TE-10 (Human
esophageal
adenocarcinoma) ESO-1
(mouse esophageal
adenocarcinoma).
Gallbladder
GBC-SD

HAG-1

Inhibition of cell proliferation via non-apoptotic form of cell
death. Caspase-3 activation was detected in two out of four
cell lines (OE21 and OE33), but was a minor event.
Apoptosis through caspase 3 activation.
Down-regulation of Cyclin D1
Down-regulate the expressions of Notch-1 specific
microRNAs, miR-21 and miR-34a, and upregulation of
tumor suppressor let-7a miRNA.
Apoptosis by regulating the ratio of Bcl-2/Bax and
activating the expression of cleaved caspase-3.
G2/M arrest and apoptosis through multiple mechanisms
involving enhanced mitogen-activated protein (MAP)
kinase activity, reduced Akt-mTOR activity, and reduced
Bcl-2 function.
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[150]

[151]

[152]

Curcumin

Cancer type/Cell
Pancreas
MIA PaCa-2

BxPC-3 and MIA PaCa-2

Description/Mechanism of action
Inhibition of cell proliferation inducing apoptosis.
Downregulation of the transcription nuclear factor
NF-κB
and NF-κB-regulated gene products
Inhibition of cell proliferation inducing apoptosis.
Activation of TNFR, CASP 8, CASP3, BID, BAX, and
down-regulation of NFκB, NDRG 1, and BCL2L10.
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Reference

[153]

[154]

Larynx
Downregulation MMP-2 expression and activity and
expression of integrin receptors, FAK, and MT1-MMP to
almost background levels. MMP-2 (but not MMP-9) mRNA
expression was abolished.

HEp2
Cervix
KB-V1

Duel modulation of MDR1 expression and Pgp function
Down-regulate HPV18 transcription as well as the AP-1
binding activity.
Reverse the expression dynamics of c-fos and fra-1.

HeLa

[155]

[156]
[157]

Ovary
HEY, OVCA429, OCC1,
SKOV3
OVCA 420 and OVCA
429

Inhibition of cell proliferation inducing p53-independent
apoptosis that involved p38 MAPK activation, ablation of
prosurvival Akt signaling, and reduced expression of the
antiapoptotic proteins Bcl-2 and surviving.
Suppression of JAK-STAT signaling via activation of PIAS3, thus attenuating STAT-3 phosphorylation and tumor cell
growth.

[158]

[159]

Prostate
LNCaP and PC-3
DU145 and PC-3

Apoptosis through Bax translocation to mitochondria and
caspase activation.
Tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL/Apo2L)-induced apoptosis by inhibiting nuclear
factor (NF)-κB.

[160]
[161]

Testis
NTera-2

Dose-dependently induced apoptosis of NTera-2 cells by
reducing FasL expression and Bcl-2-to-Bax ratio, and
activating caspase-9, -8 and -3.
Repression of AP transcription factor AP-2γ.

[162]

Kidney

Caki

ACHN

Induced apoptosis through the production of ROS, and
the down-regulation of Bcl-xL and inhibitor of apoptosis
protein (IAP) in Caki cells.
Enhanced dual PI3K/Akt and mTOR inhibitor NVPBEZ235-induced apoptosis in human renal carcinoma Caki
cells through down-regulation of p53-dependent Bcl-2
expression and inhibition of Mcl-1 protein stability.
Induced apoptosis. Up-regulation of IκB, down-regulation of
NF-κB, and modulationof the expression of the apoptosis
genes Bcl-2/Bax.
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Table 5. (Continued)

Cancer type/Cell
Brain
Glioma

Description/Mechanism of action

Reference

Induced apoptosis by inhibition of SHH/GLI1 signaling
pathway.

[165]

Thyroid
FTC-133 cell invasion was inhibited via down-regulation of
PI3K/Akt signaling pathway.
Metastasis of K1 papillary thyroid cancer cells was inhibited
via modulating E-cadherin and matrix metalloproteinase-9
expression.

FTC-133
K1

[166]
[167]

Multiple Myeloma
MM

MM

Constitutive and IL-6-inducible STAT3 phosphorylation was
inhibited.
Constitutive activation of nuclear factor-κB and IκBα kinase
in human multiple myeloma cells was down-regulated,
leading to suppression of proliferation and induction of
apoptosis.

[168]

[169]

Leukaemia
THP-1
JURKAT

Apoptosis via simultaneously targeting Akt/mTOR and
RAF/MEK/ERK survival signaling pathways.
Caspase mediated apoptosis by disrupting the redox balance.

[170]
[171]

On the other hand, curcumin demonstrated diverse anticancer properties in vitro, ex vivo
and in vivo as well as in clinical trials by inducing a variety of biological pathways involved
in apoptosis, tumor proliferation, chemoprevention, chemo- and radiosensitization, tumor
invasion, metastasis and angiogenesis. Curcumin can be an effective adjunct in treating solid
organ tumors due to its properties of regulating oncogenes like p53, egr-1, c-myc, Bcl- XL,
etc.; transcription factors like NF-kB, STAT-3, β-catenin and AP-1; growth factors (EGF,
PDGF, and VEGF); protein kinases like MAPK, Cyclin D1, CDKs, Akt, PKC; and enzymes
like COX, LOX, MMP and many others. Based on its huge therapeutic aspects several active
investigations are going on to overcome the ADME-related drawbacks by introducing new
and novel formulation and route of administration to achieve the highest therapeutic level. It
is highly expected that curcumin will become an effective cancer drug in future with novel
formulation and/or unique route of administration.
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